top of page

AI-Driven High-Throughput Drug Screening on Patient-Derived Tumor Organoids: Accelerating Precision Medicine through Novel Mechanisms of Action

Writer's picture: Christophe DebenChristophe Deben

In the pursuit of precision medicine, the DrugVision.AI platform at UZA/UAntwerp leverages robotic high-throughput drug screening on patient-derived tumor organoids combined with advanced live-cell imaging. By utilizing the Orbits Oncology AI-powered image and data analysis platform, we can process thousands of images, converting them into actionable, high-quality drug response metrics. These data are further applied by Sightera Biosciences to discover and develop novel small molecules with unique mechanisms of action (MoA), aimed at treating cancer and enhancing the efficacy of existing therapies.


This webinar showcases our integrated pipeline and features a case study on a newly identified small molecule that potentiates current cancer treatments, highlighting the future of AI-driven drug development in oncology.



1 view0 comments

Recent Posts

See All

Comments


bottom of page